SCHEMBL4569246

SCHEMBL4569246

CN(CC(C)(C)C)c1ncnc2[nH]cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.41
HSD17B10 Q99714 1/20 0.36
CHEK1 O14757 2/20 0.36
AURKA O14965 2/20 0.36
LRRK2 Q5S007 2/20 0.36
PDPK1 O15530 1/20 0.36
CHEK2 O96017 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
PRKACA P17612 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
MARK3 P27448 1/20 0.36
RPS6KA3 P51812 1/20 0.36
PRKCD Q05655 1/20 0.36
MARK2 Q7KZI7 1/20 0.36
CSF1R P07333 6/20 0.34
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5019519 0.82 HSD17B10 (0.39) HSD17B10CHEK1AURKALRRK2PDPK1
SCHEMBL4569238 0.82 HTT (0.36) HSD17B10CHEK1AURKALRRK2PDPK1
SCHEMBL4572187 0.79 HTT (0.45) HSD17B10CHEK1AURKALRRK2PDPK1
SCHEMBL4569237 0.79 JAK3 (0.35) LRRK2CSF1RJAK3
SCHEMBL29100435 0.78 LRRK2 (0.41) HSD17B10CHEK1AURKALRRK2PDPK1
Dimethyladenine SCHEMBL152593 0.78 LRRK2 (0.52) HSD17B10CHEK1AURKALRRK2PDPK1
Dimethyladenine SCHEMBL28476806 0.76 LRRK2 (0.50) HSD17B10CHEK1AURKALRRK2PDPK1
Dimethyladenine SCHEMBL11157543 0.76 LRRK2 (0.50) HSD17B10CHEK1AURKALRRK2PDPK1
SCHEMBL6517684 0.76 LRRK2 (0.42) HSD17B10CHEK1AURKALRRK2PDPK1
SCHEMBL20323084 0.76 HSD17B10 (0.38) HSD17B10CHEK1AURKALRRK2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315505-B2 Heterocyclic compounds and uses thereof INTELLIKINE LLC (US) 2016-04-19 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20140296207-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. 2014-10-02 US disclosed
US-8785454-B2 Heterocyclic compounds and uses thereof INTELLIKINE LLC (US) 2014-07-22 US disclosed
US-20120329776-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. 2012-12-27 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB NUDT1 869/4885HSD17B10 1927/4885CHEK1 248/4885
US-20140296207-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, AKT3, PIK3CD NUDT1 916/4885HSD17B10 2578/4885CHEK1 170/4885
US-20120329776-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB NUDT1 576/4885HSD17B10 1602/4885CHEK1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.